Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 25, 2011

SUNY at Buffalo Selects Sage-N's Sorcerer Platform for Proteomics Work

  • The State University of New York (SUNY) at Buffalo has chosen the Sage-N Research Sorcerer™ platform for its proteomics research. The university's Lab of Clinical Proteomics and Pharmaceutical Analysis, led by Jun Qu, Ph.D., selected the Sequest® 3G search engine and Matrix Science’s Mascot®, a search engine that uses mass spectrometry data to identify proteins from primary sequence databases.

    Both are hosted on the Sorcerer platform, which is designed to support multiple software programs. The Sorcerer will replace the current supercomputers that are used within the university’s laboratory. The technology will handle up to a terabyte of information generated by a long-gradient nanoliquid chromatography mass spectrometer (nano-LC/MS) developed in Dr. Qu's lab.

    “For example, 60k–80k spectra were generated by a single nano-LC/MS run of a clinical sample. In our lab, one typical clinical project will involve the analysis of 2–3 millions of spectra,” Dr. Qu says.

    SUNY at Buffalo will use the technology in a variety of applications including diagnostic and biomarker discovery for cardiovascular diseases, colon, pancreatic and prostate cancers, cocaine addiction, retina degeneration, COPD, and HIV.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »